Disease · MONDO_0005249
Comparisons in its trials100
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 100
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Enhanced Treatment vs Current Practice: serious adverse events | 6 of 1,017 | 15 of 2,108 | 3,125 | NCT00513500 | Trial comparisons |
| Enhanced Treatment vs Current Practice: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine) | 265 of 963 | 2,066 of 2,084 | 3,047 | NCT00513500 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants Who Received at Least One Dose of Study Drug and Reported an Adverse Event | 295 of 353 | 303 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Organ Failure | 69 of 353 | 67 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants Who Received at Least One Dose of Study Drug and Reported a Serious Adverse Event | 101 of 353 | 97 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale 400mg q12h vs Placebo: deaths from any cause | 86 of 353 | 85 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale 400mg q12h vs Placebo: serious adverse events | 101 of 353 | 97 of 359 | 712 | NCT01799993 | Trial comparisons |
| Enhanced Treatment vs Current Practice: Number of Children Who do Not Respond to Treatment for Pneumonia | 41 of 362 | 41 of 203 | 565 | NCT00513500 | Trial comparisons |
| Amoxicillin vs Penicillin: Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First) | 30 of 263 | 29 of 263 | 526 | NCT01399723 | Trial comparisons |
| Amoxicillin vs Penicillin: Treatment Failure at 48 Hours (Two Full Days After Enrollment) | 20 of 263 | 21 of 263 | 526 | NCT01399723 | Trial comparisons |
| Amoxicillin vs Benzyl Penicillin: serious adverse events | 1 of 263 | 3 of 263 | 526 | NCT01399723 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Microbiological Response at TOC Visit | 150 of 255 | 118 of 253 | 508 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Emergence of New Respiratory Pathogens During the Aerosol Treatment Period | 21 of 255 | 34 of 253 | 508 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Microbiological Recurrence at LFU Visit | 12 of 255 | 12 of 253 | 508 | NCT01799993 | Trial comparisons |
| Amoxicillin vs Penicillin: Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview | 33 of 244 | 42 of 250 | 494 | NCT01399723 | Trial comparisons |
| Opaganib vs Placebo: Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement With a Scale Ranging From 8 Down to 0 | 145 of 230 | 138 of 233 | 463 | NCT04467840 | Trial comparisons |
| Opaganib vs Placebo: Number of Participants With Low Oxygen Flow Via Nasal Cannula | 169 of 230 | 167 of 233 | 463 | NCT04467840 | Trial comparisons |
| Opaganib vs Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 155 of 230 | 147 of 233 | 463 | NCT04467840 | Trial comparisons |
| Opaganib vs Placebo: deaths from any cause | 44 of 230 | 47 of 233 | 463 | NCT04467840 | Trial comparisons |
| Opaganib vs Placebo: serious adverse events | 52 of 230 | 52 of 233 | 463 | NCT04467840 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005249/comparisons